CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 160 enrolled
Drug / intervention
Escitalopram +1 moredrug
Likely dose
Escitalopram 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00536172
NCT00536172Phase 4Completed
CompareCT.gov

Prevention of Depression in Patients Being Treated for Head and Neck Cancer

University of Nebraska·interventional·Posted Sep 27, 2007·Updated Sep 21, 2023

In Brief

A Phase 4 clinical trial evaluating Escitalopram and Placebo for Depression. Completed, enrolled 160 participants across 1 site.

Detailed Summary

This study will evaluate the effectiveness of escitalopram to prevent depression in head and neck cancer patients receiving treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 27, 2007
Enrollment StartDec 1, 2007
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 18.8 years ago

Interventions

Escitalopramdrug

Participants take 10 mg for 1 week and then 20 mg for 15 weeks.

Placebodrug

Placebo distribution matches the active medication.